1. Simren M, Dore J. Gut Microbiota for Health – Current Insights and Understanding. Eur Gastroenterol Hepatol Rev 2012.
2. Dore J, Simren M, Buttle L, Guarner F. Hot topics in gut microbiota. United Eur Gastroenterol J 2013; 1 (5): 311–3.
3. Hutchinson L. Liver cancer: Gut microbiota feeds obesity-induced liver cancer. Nat Rev Clin Oncol 2013; 10 (8): 428.
4. Muegge B. Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science 2011; 
332: 970–4.
5. Ley RE, Backhed F, Turnbaugh PJ et al. Obesity alters gut microbial ecology. Proc Nat Acad Sci USA 2005; 102 (31): 11070–5.
6. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology human gut microbes associated with obesity. Nature 2006; 444 (7122): 1022–3.
7. Donovan SM. Promoting bifidobactera in the human infant intestine: why, how and which? J Ped Gasroenterol Nutr 2011; 52 (6): 648–50.
8. Schwiertz A, Taras D, Schafer K et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 2010; 18 (1): 190–5.
9. Everard A, Belzer C, Geurts L et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013; 110 (22): 9066–71.
10. Stock J. Gut microbiota: an environmental risk factor for cardiovascular disease. Atherosclerosis 2013; 229 (2): 440–2.
11. Akira S, Sato S. Toll-like receptors and their signaling mechanisms. Review. Scand J Infect Dis 2003; 35 (9): 555–62.
12. Fraunberger P, Gröne E, Gröne HJ, Walli AK. Simvastatin reduces endotoxin-induced nuclear factor kappaB activation and mortality in guinea pigs despite lowering circulating low-density lipoprotein cholesterol. Shock 2009; 32 (2): 159–63.
13. Лиходед В.Г., Бондаренко В.М. Микробный фактор и toll-подобные рецепторы в патогенезе атеросклероза. Журн. микробиологии, эпидемиологии и иммунобиологии. 2009; 6: 107–12.
14. Satoh M, Shimoda Y, Akatsu T et al. Elevated сirculating levels of heat shock protein 70 are related to systemic inflammation reaction through monocyte Toll signal in patients with heart failure after acute myocardial infarction. Eur Soc Cardiol 2006, 8: 810–5.
15. Бондаренко В.М., Лиходед В.Г., Яковлев М.Ю. Определение эндотоксина грамотрицательных бактерий в крови человека. Журн. микробиологии. 2002; 2: 83–9.
16. Reinhardt C Reigstad CS, Backhed F. Intestinal microbiota during infancy and its implications for obesity. J Ped Gastroenterol Nutr 2009; 48: 249–56.
17. Shi H, Kokoeva MV, Inouye K et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116: 3015–25.
18. Pierre N, Deldicque L, Barbé C et al. Toll-like receptor 4 knockout mice are protected against endoplasmic reticulum stress induced by a high-fat diet. PLoS One 2013; 31 (8): 5.
19. Caesar R, Fak F, Backhed F. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. J Intern Med 2010; 268: 320–8.
20. Feuerer M. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect methabolic parameters. Nature Med 2009; 15: 930–9.
21. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Ann Rev Immunol 2011; 29: 415–45.
22. Reigstad CS, Lunden GO, Felin J, Backhed F. Regulation of serum amyloid A3 (SAA3) in mouse colonic epithelium and adipose tissue by the intestinal microbiota. PloS One 2009; 4: 5842.
23. Ghoshal S, Witta J, Zhong J et al. Chilomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009; 50: 90–7.
24. Brun P, Castagliolo I, Leo VD et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 
292: G518–25.
25. Cani PD, Possemiers S, Van de Wiele T et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58: 1091–103.
26. Cani PD, Everard A, Duparc T. Gut microbiota, enteroendocrine functions and metabolism. Curr Opin Pharmacol 2013; doi:pii: S1471-4892(13)00168-9.
27. Cani PD. Gut microbiota and obesity: lessons from the microbiome. Brief Funct Genomics 2013; 12 (4): 381–7; doi: 10.1093/bfgp/elt014. Epub 2013 Apr 24.
28. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nature Immunol 2004; 5 (10): 975–9.
29. Бондаренко В.М., Гинцбург А.Л., Лиходед В.Г. Роль инфекционного фактора в патогенезе атеросклероза. Эпидемиология и инфекц. болезни. 2011; 1: 7–12.
30. Конев Ю.В., Лазебник Л.Б. Метаболизм эндотоксина в организме и его роль в процессах инволюции. Клин. геронтология. 2009; 1 (15): 39–46.
31. Конев Ю.В. Эндотоксин (ЛПС) и атеросклероз. Эксперим. и клин. гастроэнтерология. 2011; 11: 24–32.
32. Saberi M, Woods NB, de Luca C et al. Hematopoetic cellspecific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab 2009; 10: 419–29.
33. Caesar R, Fak F, Backhed F. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. J Intern Med 2010; 268: 320–8.
34. Бондаренко В.М., Грачева Н.М., Мацулевич Т.В. Дисбактериозы кишечника у взрослых. М.: КМК Scientific Press, 2003.
35. Яковлев М.Ю., Лиходед В.Г., Пермяков Н.К., Конев Ю.В. Эндотоксининдуцированные повреждения эндотелия. Арх. патологии. 1996; 2 (58): 41–7.
36. О диiэтическомъ значенiи «кислаго молока» проф. Мечникова. Клиническiя наблюденiя из СПБ морского госпиталя доктора Г.А.Макарова. Изданiе К.Л.Риккерса Невский пр. 14. 1907 г.
37. Конев Ю.В. Эндотоксин и метаболический синдром. Эксперим. и клин. гастроэнтерология. 2012; 11: 26–34.
38. Лазебник Л.Б., Конев Ю.В. Микробиота толстой кишки и составляющие метаболического синдрома. Эксперим. и клин. гастроэнтерология. 2014; 5: 4–10.

Л.Б.Лазебник, Ю.В.Конев

Кафедра терапии, гериатрии и профилактики ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России